Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.62 USD

38.62
1,445,689

+0.26 (0.68%)

Updated Aug 7, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2

by Zacks Equity Research

Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.

    Zacks Equity Research

    What's in Store for Epizyme (EPZM) This Earnings Season?

    by Zacks Equity Research

    Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.

      Zacks Equity Research

      What's in Store for Immune Design (IMDZ) in Q2 Earnings?

      by Zacks Equity Research

      We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.

        Zacks Equity Research

        Is Exelixis (EXEL) Poised for a Beat Again in Q2?

        by Zacks Equity Research

        Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.

          Zacks Equity Research

          AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up

          by Zacks Equity Research

          AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.

            Zacks Equity Research

            Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales

            by Zacks Equity Research

            Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.

              Zacks Equity Research

              What's in Store for ImmunoGen (IMGN) This Earnings Season?

              by Zacks Equity Research

              ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.

                Zacks Equity Research

                Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up

                by Zacks Equity Research

                Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.

                  Zacks Equity Research

                  Celgene (CELG) Q2 Earnings: Disappointment in Store?

                  by Zacks Equity Research

                  Celgene Corporation (CELG) has been sailing in troubled waters, of late, and the recent pipeline setbacks might weigh on its performance in its second-quarter results.

                    Zacks Equity Research

                    BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions

                    by Zacks Equity Research

                    Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.

                      Zacks Equity Research

                      Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

                      by Zacks Equity Research

                      J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

                        Zacks Equity Research

                        Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion

                        by Zacks Equity Research

                        Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.

                          Zacks Equity Research

                          Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study

                          by Zacks Equity Research

                          Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).

                            Zacks Equity Research

                            Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

                            by Zacks Equity Research

                            On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

                              Zacks Equity Research

                              Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

                              by Zacks Equity Research

                              The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

                                Zacks Equity Research

                                Roche's Flu Drug Meets Primary Endpoint in Phase III Study

                                by Zacks Equity Research

                                Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.

                                  Zacks Equity Research

                                  AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

                                  by Zacks Equity Research

                                  AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

                                    Zacks Equity Research

                                    Celgene Reports Positive Data on Tecentriq, Abraxane Study

                                    by Zacks Equity Research

                                    Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.

                                      Zacks Equity Research

                                      Celgene, Acceleron Report Positive Data on Thalassemia Drug

                                      by Zacks Equity Research

                                      Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.

                                        Zacks Equity Research

                                        CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

                                        by Zacks Equity Research

                                        CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.

                                          Zacks Equity Research

                                          Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?

                                          by Zacks Equity Research

                                          Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.

                                            Zacks Equity Research

                                            Bristol-Myers' Sprycel Gets EC Approval for Label Expansion

                                            by Zacks Equity Research

                                            Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.

                                              Zacks Equity Research

                                              Should Value Investors Consider Roche Holding (RHHBY) Stock?

                                              by Zacks Equity Research

                                              Let's put Roche Holding (RHHBY) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                                                Zacks Equity Research

                                                Roche's Breast Cancer Study Meets Co-Primary Endpoint

                                                by Zacks Equity Research

                                                Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

                                                  Zacks Equity Research

                                                  Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

                                                  by Zacks Equity Research

                                                  Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.